{'fraction_non_alphanumeric': 0.017045454545454544, 'fraction_numerical': 0.005681818181818182, 'mean_word_length': 5.080459770114943, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Observations on the efficacy of L-dopa in progressive supranuclear palsy.

The long-term effect of L-dopa in 3 patients with progressive supranuclear palsy is described and 10 other cases previously reported are summarized. L-dopa has a significant effect on the parkinsonian features of PSP but does not have any significant effect on the specific non-parkinsonian features such as ophthalmoplegia and neck dystonia. The implications of this difference are discussed in relation to the pathophysiology of the separate symptoms.